利奈唑胺治疗耐甲氧西林金黄色葡萄球菌感染的疗效及安全性分析  

The analysis on effect and safety of Linezolid in the treatment of MRSA infection

作　　者：范大平[1] 张一梅[1] 尚建欣[1] 

机构地区：[1]哈尔滨医科大学附属第一临床医学院呼吸内科,黑龙江哈尔滨150001

出　　处：《临床肺科杂志》2011年第10期1520-1521,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的观察利奈唑胺的疗效及安全性。方法选择接受利奈唑胺治疗的22例患者,观察患者临床症状、体征、影像学改变等。结果 22例中10例治愈,7例好转,有效率77.27%,无效5例,其中2例死亡,2例自动出院,1例白细胞进行性升高出现黄疸后考虑为血液病而转科治疗。3例白细胞降低至正常范围以下,2例血小板降低,3例合并肾功能异常及9例合并肝功能异常患者,在应用利奈唑胺后肝肾功结果未见明显升高。结论利奈唑胺是治疗耐甲氧西林金黄色葡萄球菌感染既有效又安全的药物。Objective Observe efficiency and safety of Linezolid,and provide references for the rational use of drugs.Methods Select 22 cases of treated patients by Linezolid between Jun 2009 to Aug 2010 from respiratory medicine in Harbin medical university first affiliated hospital.Observe clinical symptoms and signs of fever during the treatment,vital signs,imaging change.Monitor CBC,liver and kidney functions and patholochange.Results 10 cases in 22 cases cured,7 cases improved,the efficiency is 77.27%.5 cases didn’t benefit from the treatment（including 2 deaths and 2 cases of automatic discharge）.3 cases with white blood cells dropped below normal;2 cases with platelet decreased;For the 3 cases with renal dysfunction and 9 cases with abnormal liver function,after the treatment of Linezolid liver and renal function has not been significantly increased.Conclusion Linezolid as the treatment of Methicillin-resistant Staphylococcus aureus（MRSA） infections is effective and safe.For patients who have high risk of MRSA infection Linezolid can be a preventable medication.

关 键 词：利奈唑胺 耐甲氧西林金黄色葡萄球菌 

分 类 号：R969[医药卫生—药理学]